Biogen (BIIB) and Gilead (GILD) on Torvanta's measures: BIIB grades higher on 1 of the 4 factor families and GILD on 2.
| BIIB | GILD | |
|---|---|---|
| Value grade | B | n/a |
| Growth grade | D | C- |
| Profitability grade | n/a | C |
| Momentum grade | B+ | B+ |
| Market value | n/a | $193.7B |
| P/E (trailing) | n/a | n/a |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $9.9B | $30.5B |
| Revenue growth (y/y) | n/a | +6% |
| Operating margin | 23.2% | -8.2% |
| Return on invested capital | n/a | -5.7% |
| Free-cash-flow yield | 8.4% | 6.7% |
| Total return, 1 year | +63.5% | +35.8% |
| Total return, 3 years | -13.2% | +116.7% |
Full BIIB analysis · Full GILD analysis
Biogen (BIIB) and Gilead (GILD) on Torvanta's measures: BIIB grades higher on 1 of the 4 factor families and GILD on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings BIIB trades at n/a and GILD at n/a; their value grades are B and n/a against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer